SCHEMBL6915017

SCHEMBL6915017

CCNC(=N)NS(=O)(=O)c1sc(Cl)cc1B(O)O

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6802653 0.86 MEN1 (0.40) ALDH1A1
SCHEMBL6911507 0.82
SCHEMBL6807241 0.81
SCHEMBL6800094 0.79
SCHEMBL7566282 0.77 CDK1 (0.46) ALDH1A1
SCHEMBL6915023 0.75 LMNA (0.37) ALDH1A1
SCHEMBL6804436 0.72 KMT2A (0.49) ALDH1A1
SCHEMBL6911509 0.70 MALT1 (0.32) ALDH1A1
SCHEMBL7562968 0.67 CDK1 (0.44) ALDH1A1
SCHEMBL6807252 0.64 CCR4 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040010142-A1 Novel process NOVO NORDISK A/S (DK) 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010142-A1 Novel process UGT1A1, CYP4X1, CYP4B1 ALDH1A1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.